I motsetning til Wegovy som er monoagonist (kun GLP-1), er Retatrutide en trippel agonist
Include whole grains, fruits, vegetables, lean meats, and healthy fats in meals
The SURPASS-CVOT trial, where dulaglutide at the dose of 1.5 mg/week or at the highest tolerated dose, is the comparator, has a distinctive design from the other trials: the primary endpoint is the time to the first manifestation of any major adverse CV event (MACE), defined as myocardial infarction, stroke or CV death
In contrast, cohort studies provide better-defined populations and follow-up but remain vulnerable to subjective reporting and confounding
Preclinical studies suggest that GLP-1 receptor activation can reduce inflammatory cytokine production and modulate immune responses in ways that could be protective against infection